The study of the Chloroquine, which is used for the treatment of COVID-19, was partially discontinued due to the risk of fatal complications.
In Brazil, stopped the stage of research of the Chloroquine in patients with coronavirus disease, reports the New York Times.
Note that this is from the group of antimalarial, which is also in the Ukrainian treatment Protocol COVID-19.
In particular, 81 hospitalized patients took part in the study. Approximately half of the participants were given a dose of 450 mg of Chloroquine twice a day for 5 days. Others were given a higher dose of 600 mg for 10 days.
Within three days, researchers began noticing heart arrhythmias in patients who took a high dose. By the sixth day of treatment, 11 patients had died, so the study phase with high doses of the was discontinued.
Patients in the study were also given the antibiotic azithromycin, which also causes a risk of heart rhythm disorders.
The researchers said they did not have enough patients taking low doses to conclude whether Chloroquine was effective for patients with severe COVID-19. According to them, additional research is needed to evaluate the effectiveness of the in the early stages of the disease.
According to the latest data, more than 1.8 million cases of COVID-19 infection were recorded in the world, more than 114 thousand people died, and more than 423 thousand recovered. In Canada, more than 24 thousand people were infected and 717 died.